IperionX Ltd (NASDAQ:IPX) Chief Executive Officer Anastasios Arima reported insider purchases on March 27, 2026 that together amounted to $1.79 million, according to a Form 4 filed with the Securities and Exchange Commission.
The filing records acquisitions of 467,000 Ordinary Shares and 12,800 American Depository Shares (ADS), with transaction prices spanning from $3.198 to $23.4097 per share. Following these buys, Arima is listed as directly owning 12,206,782 Ordinary Shares and 12,800 ADS.
In addition to the shares acquired on March 27, the filing details Arima's outstanding equity awards. He holds 738,576 Restricted Stock Units (RSUs), of which 318,666 are scheduled to vest in December 2026 and 419,910 are set to vest in April 2028. The filing also notes that Arima holds Performance Rights.
Market context supplied in the filing and related materials shows IperionX shares trading at $23.15 at the time of the report. That price point marks a 53% decline over the prior six months but represents a 28% gain over the past year. An InvestingPro analysis referenced in the report indicates the stock is trading slightly above its Fair Value, while analyst price targets cited range from $40 to $71.
Separate analyst activity highlighted in the filing and accompanying notes shows BTIG initiating coverage with a Buy rating and a $40.00 price target. William Blair also began coverage with an Outperform rating. Both firms' coverage coincides with IperionX commencing commercial production at its Virginia plant.
Company production plans cited in the filing and analyst commentary outline an initial output target of roughly 200 tonnes per annum (tpa) from the Virginia facility, with plans to expand production to about 1,400 tpa in the following year. William Blair's coverage notes the company's potential to scale operations substantially and suggests IperionX could become a leading domestic producer of titanium powder, including component manufacturing.
The Form 4 disclosure, combined with analyst notes and production updates, presents a snapshot of insider activity, current market pricing, and operational milestones for IperionX as the company moves into commercial production.